What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1308039

Cover Image

PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1308039

Global Tissue-engineered Skin Substitute Growth Opportunities

PAGES: 78 Pages
DELIVERY TIME: 1-2 business days
Web Access (Regional License)
USD 4950

Add to Cart

Breakthrough Technologies and Competitive Intensity Drive Innovation

Rising incidents of burn injuries, road accidents, and other trauma injuries, along with increasing cases of chronic wounds, such as diabetic ulcers and venous ulcers, are boosting the global tissue-engineered skin substitutes (TESS) market. Moreover, the increasing number of surgical injuries, plastic surgeries, cosmetic surgeries, and other reconstructive surgeries is expected to propel market growth during the forecast period (2023-2027). In 2022, the market witnessed a huge revenue spike as the backlog of skin substitute procedures postponed due to the COVID-19 pandemic started to be cleared.

This Frost & Sullivan study analyzes the global TESS market, including market landscape by end users, application types, therapy types, and market share percentage by market participants. It also examines macroeconomic factors, the latest trends, revenue forecasts, the US regulatory landscape, and next-generation TESS technologies and solutions. The study period is from 2022 to 2027, and the base year is 2022.

The study also highlights specific market growth opportunities, with a focus on disruptive innovation, new unaddressed markets, and the growing prevalence of cosmetic tourism. It excludes the bone grafts market for bone regeneration and repair and the market for artificial organs created with the help of allografts, such as allograft aortic valves in cardiac applications.

New application areas for skin substitutes, including plastic surgeries, reconstructive surgeries, and post-surgical wound healing, are expec

ted to increase during the forecast period and boost TESS market growth. A wide range of specialized surgical applications, such as facial plastic surgery, dermal fillers, and root therapy, use synthetic TESS for reconstructive and repair purposes. Other applications include face-lifts, breast augmentations, and limb or back additions. Moreover, the introduction of advanced products, including cellular and acellular skin spray products, suggests advanced usage in clinical dermatology for complex wound healing. Plastic surgeons are also increasingly using skin substitutes to treat several types of cutaneous defects without minimizing donor sites.

Novel skin substitute types in the form of injectables, particulates, and sprays are entering the TESS space along with innovative manufacturing technologies, enabling the faster development of skin substitutes and resulting in new features that accelerate wound healing. Customers are also demanding less-expensive products that offer longer shelf-life; these products must also be easily available and offer hassle-free application as well as low-to-zero infection at the application site. Particulate (powder form) placental extra-cellular matrix (ECM), spray-on skin substitutes, 3D bioprinted skin substitutes, and platelet-rich plasma (PRP) injections are some next-generation solutions and technologies the study analyzes.

The study also touches upon CMS policies for skin substitute products announced in July 2022, which state that skin substitutes will be called wound care management products to aptly mirror how clinicians use them, enabling more consistent and transparent product coding. Biological skin substitutes dominate the market as the adoption of and preference for these products is higher than the other 2 types. Though biosynthetic skin substitutes treat moderate-to-severe burns, the synthetic segment is expected to witness faster growth than biosynthetic skin substitutes, mainly due to the rising technological advancements in biomaterials. Synthetic skin substitutes demonstrate increased control over scaffold composition.

Product Code: K8FA-54

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Tissue-engineered Skin Substitutes Market
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Scope of Analysis
  • Segmentation
  • Key Competitors-Acellular Skin Substitutes
  • Key Competitors-Cellular Skin Substitutes
  • TESS Landscape by Market Participants
  • TESS Landscape by End Users
  • TESS Landscape by Applications
  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Tissue-engineered Skin Substitutes-What are They?
  • Classification of Skin Substitutes by Origin, Components, and Durability
  • TESS Definitions by Wound Type
  • TESS Selection Based on Wound Type
  • Transition from Traditional to Advanced Wound Management Products
  • TESS Definitions by Skin Graft Types
  • TESS Definitions by Acellular Therapy Types
  • TESS Definitions by Cellular Therapy Types
  • Skin Substitute Usage-Pros and Cons
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast by Segment
  • Revenue Forecast by Region
  • Forecast Analysis
  • Competitive Environment

TESS Regulatory Landscape-The United States

  • Wound Care Supplies Medicare Covers
  • Wound Care Supplies Medicare Does Not Cover
  • Wound Care Coverage-An Overview
  • US FDA Regulatory Status for Skin Substitute Products
  • Skin Substitute Reimbursement Scenario-Synthetic Substitutes
  • What's New for Skin Substitute Products in 2023?

Market Participants' Offerings

  • Market Participants' Products-Acellular Skin Substitutes
  • Market Participants' Products-Cellular Skin Substitutes
  • Top Wound Care Companies to Watch

Next-generation TESS Technologies and Solutions

  • Traditional versus New Application Areas
  • Particulate Placental ECM Device for Wounds and Burns-ConvaTec's InnovaMatrix® PD
  • Spraying on Skin Cells to Accelerate Burn Healing
  • 3D Bioprinted Skin Substitutes
  • Platelet-rich Plasma (PRP) Injections

Growth Opportunity Universe

  • Growth Opportunity 1: Disruptive TESS Innovation
  • Growth Opportunity 2: Growing Cosmetic Tourism
  • Growth Opportunity 3: Government Support and Reimbursements for Advanced Wound Healing
  • Growth Opportunity 4: Targeting the APAC Region
  • Growth Opportunity 5: Sensor-based Skin Patches and Electronic Skin

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!